These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

80 related articles for article (PubMed ID: 17551386)

  • 61. C-reactive protein, anti-C-reactive protein antibodies and clinical atherosclerosis.
    Rosenau BJ; Costenbader KH; Schur PH
    Vasc Med; 2008 Feb; 13(1):25-8. PubMed ID: 18372435
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Basic science for the clinician 44: atherosclerosis: an immunologically mediated (autoimmune?) disease.
    Sigal LH
    J Clin Rheumatol; 2007 Jun; 13(3):160-8. PubMed ID: 17551386
    [TBL] [Abstract][Full Text] [Related]  

  • 63. The pathogenesis of atherosclerosis in autoimmune rheumatic diseases: roles of inflammation and dyslipidemia.
    Hahn BH; Grossman J; Chen W; McMahon M
    J Autoimmun; 2007; 28(2-3):69-75. PubMed ID: 17433865
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Antibodies to oxidized low density lipoprotein: epidemiological studies and potential clinical applications in cardiovascular disease.
    Gounopoulos P; Merki E; Hansen LF; Choi SH; Tsimikas S
    Minerva Cardioangiol; 2007 Dec; 55(6):821-37. PubMed ID: 18091649
    [TBL] [Abstract][Full Text] [Related]  

  • 65. The role of phospholipid oxidation products in inflammatory and autoimmune diseases: evidence from animal models and in humans.
    Leitinger N
    Subcell Biochem; 2008; 49():325-50. PubMed ID: 18751917
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Oxidation-specific epitopes are important targets of innate immunity.
    Chou MY; Hartvigsen K; Hansen LF; Fogelstrand L; Shaw PX; Boullier A; Binder CJ; Witztum JL
    J Intern Med; 2008 May; 263(5):479-88. PubMed ID: 18410591
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Vascular cells contribute to atherosclerosis by cytokine- and innate-immunity-related inflammatory mechanisms.
    Loppnow H; Werdan K; Buerke M
    Innate Immun; 2008 Apr; 14(2):63-87. PubMed ID: 18713724
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Preventing autoimmune and infection triggered atherosclerosis for an enduring healthful lifestyle.
    Matsuura E; Kobayashi K; Lopez LR
    Autoimmun Rev; 2008 Jan; 7(3):214-22. PubMed ID: 18190881
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Vaccines modulating lipoprotein autoimmunity as a possible future therapy for cardiovascular disease.
    Nilsson J; Fredrikson GN; Björkbacka H; Chyu KY; Shah PK
    J Intern Med; 2009 Sep; 266(3):221-31. PubMed ID: 19702790
    [TBL] [Abstract][Full Text] [Related]  

  • 70. The paradox of dysfunctional high-density lipoprotein.
    Ansell BJ; Fonarow GC; Fogelman AM
    Curr Opin Lipidol; 2007 Aug; 18(4):427-34. PubMed ID: 17620860
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Autoimmunity in atherosclerosis: a protective response losing control?
    Nilsson J; Hansson GK
    J Intern Med; 2008 May; 263(5):464-78. PubMed ID: 18410590
    [TBL] [Abstract][Full Text] [Related]  

  • 72. The two faces of the 15-lipoxygenase in atherosclerosis.
    Wittwer J; Hersberger M
    Prostaglandins Leukot Essent Fatty Acids; 2007 Aug; 77(2):67-77. PubMed ID: 17869078
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Inflammation and immunity in diabetic vascular complications.
    Nilsson J; Bengtsson E; Fredrikson GN; Björkbacka H
    Curr Opin Lipidol; 2008 Oct; 19(5):519-24. PubMed ID: 18769234
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Toll-like receptors in atherosclerosis.
    Tobias PS; Curtiss LK
    Biochem Soc Trans; 2007 Dec; 35(Pt 6):1453-5. PubMed ID: 18031244
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Influence of CD4+/CD25+ regulatory T cells on atherogenesis in patients with end-stage kidney disease.
    Meier P; Meier R; Blanc E
    Expert Rev Cardiovasc Ther; 2008 Aug; 6(7):987-97. PubMed ID: 18666849
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Natural antibodies against phosphorylcholine in cardiovascular disease.
    de Faire U; Frostegård J
    Ann N Y Acad Sci; 2009 Sep; 1173():292-300. PubMed ID: 19758165
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Innate immunity, macrophage activation, and atherosclerosis.
    Yan ZQ; Hansson GK
    Immunol Rev; 2007 Oct; 219():187-203. PubMed ID: 17850490
    [TBL] [Abstract][Full Text] [Related]  

  • 78. The fine-tuning of anti-oxidized low-density lipoprotein antibodies in cardiovascular disease and thrombosis.
    Freire de Carvalho J; Sherer Y; Shoenfeld Y
    Thromb Haemost; 2007 Dec; 98(6):1157-9. PubMed ID: 18064307
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Adaptive immunity in atherogenesis: new insights and therapeutic approaches.
    Lichtman AH; Binder CJ; Tsimikas S; Witztum JL
    J Clin Invest; 2013 Jan; 123(1):27-36. PubMed ID: 23281407
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Inflammatory and autoimmune mechanisms in the induction of atherosclerotic damage in systemic rheumatic diseases: two faces of the same coin.
    Bartoloni E; Shoenfeld Y; Gerli R
    Arthritis Care Res (Hoboken); 2011 Feb; 63(2):178-83. PubMed ID: 20740611
    [No Abstract]   [Full Text] [Related]  

    [Previous]     [New Search]
    of 4.